 |
|
|
| |
Routinely Available Noninvasive Tests Discriminate Advanced Fibrosis Due to NASH in the Phase 3 STELLAR Trials of the ASK1 Inhibitor Selonsertib
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting® 2018, November 9-13, 2018, San Francisco, CA
Quentin M. Anstee,1 Eric J. Lawitz,2 Naim Alkhouri,2 Vincent Wai-Sun Wong,3 Manuel Romero-Gomez,4 Takeshi Okanoue,5 Michael Trauner,6 Kathryn Kersey,7 Georgia Li,7 G. Mani Subramanian,7 Robert P. Myers,7 C. Stephen Djedjos,7 Ling Han,7 Yao Li,7 Tuan Nguyen,7 Anita Kohli,8 Natalie Bzowej,9 Ziad Younes,10 Shiv Sarin,11 Mitchell L. Shiffman,12 Stephen A. Harrison,13 Zachary Goodman,14 Zobair M. Younossi14
1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; 2Texas Liver Institute, UT Health San Antonio, TX; 3The Chinese Hospital of Hong Kong; 4Hospital Universitario Virgen del Rocio, Sevilla, Spain; 5Saiseikai Suita Hospital, Suita, Japan; 6Medizinische Universitat Wien, Austria; 7Gilead Sciences, Inc., Foster City, CA; 8Institute for Liver Health, Chandler, AZ; 9Ochsner Medical Center, New Orleans, LA; 10Gastro One, Germantown, TN; 11Institute of Liver & Biliary Sciences, New Delhi, India; 12Bon Secours Liver Institute of Richmond, Virginia; 13Pinnacle Research, San Antonio; 14Inova Fairfax Hospital, Falls Church, VA
References: 1. Rockey DC, et al. Hepatology 2009;49:1017-44; 2. Mehta SH, et al. J Hepatol 2009;50:36-41; 3. Angulo P, et al. Hepatology 2007;45:846-54; 4. Lichtinghagen R, et al. J Hepatol 2013;59:236-42; 5. Shah AG, et al. Clin Gastroenterol Hepatol 2009;7:1104-12; 6. Tapper EB, et al. Am J Gastroenterol 2016;111:677-84; 7. Petta S, et al. J Hepatol 2017;66:S591. Acknowledgments: We extend our thanks to the patients and their families. These studies were funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
